Current status of methods to assess cancer drug resistance

International Journal of Medical Sciences

Volumn 8, Issue 3, 2011, Pages 245-253

  Lippert, Theodor H ^a   Ruoff, Hans Jörg ^a   Volm, Manfred ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer biomarker tests; Cancer drug resistance; In vitro cancer drug resistance tests; In vivo cancer drug re sistance tests

Indexed keywords

ALPHA FETOPROTEIN; BCR ABL PROTEIN; BIOLOGICAL MARKER; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; PROSTATE SPECIFIC ANTIGEN; STEM CELL FACTOR RECEPTOR; TRASTUZUMAB; TUMOR MARKER;

BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER LOCALIZATION; CANCER RESEARCH; CANCER RESISTANCE; CANCER STAGING; CANCER TEST; CHEMOSENSITIVITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; COLORECTAL CANCER; DRUG TREATMENT FAILURE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PROTEIN TARGETING; REVIEW; SENSITIVITY ANALYSIS;

EID: 79955542346     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8.245     Document Type: Review

References (74)

1. Pinedo HM, Giaccone G: Drug Resistance in the Treatment of Cancer. Cambridge: Cambridge University Press; 1998.
2. Lippert TH, Ruoff HJ, Volm M: Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeu-tic failure. Arzneimittel-Forschung. 2008; 58: 261-264.
3. Mellor HR, Callaghan R: Resistance to chemotherapy in cancer: A complex and integrated cellular response. Pharmacology. 2008; 81: 275-300.
4. Widakowich C, de Castro G, de Azambuja E, Dink P, Awada A: Review: Side effects of approved molecular targeted therapies in solid cancers. Oncologist. 2007; 12: 1443-1455.
5. Tanneberger St: Gewebekultur und Krebschemotherapie. Arch Geschwulstforsch. 1968; 31: 387-400.
6. Cree IA, Glaysher S, Harvey AL: Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol. 2010; 10: 375-379.
7. Masters JRW. Human Cancer in Primary Culture, A Handbook. Dodrecht: Kluwer Academic Publishers; 1991.
8. Pfragner R, Freshney RIJ: Culture of Human Tumor Cells. Ho-boken, New Jersey: Wiley-Liss; 2004.
9. Paraskeva C, Hague A. Colorectum. In: Masters JRW, ed. Hu-man Cancer in Primary Culture, A Handbook. Dodrecht: Kluwer Academic Publishers. 1991: 151-168.
10. Park J-G, Ku J-L, Kim H-S, Park S-Y, Rutten MJ. Culture of normal and malignant gastric epithelium. In: Pfragner R, Freshney RI, eds. Culture of Human Tumor Cells. Hoboken, New Jersey: Wiley and Sons. 2004: 23-66.
11. Whitehead RH. Establishment of cell lines from colon carcino-ma. In: Pfragner R, Freshney RI, eds. Culture of Human Tumor Cells. Hoboken, New Jersey: Wiley and Sons. 2004: 67-80.
12. Pera MF. Testicular Germ Cell tumours. In: Masters JRW, ed. Human Cancer in Primary Culture, A Handbook. Dodrecht: Kluwer Academic Publishers. 1991: 169-185.
13. Parkinson EK, Yeudall WA. Epidermis. In: Masters JRW, ed. Human Cancer in Primary Culture, A Handbook. Dodrecht: Kluwer Academic Publishers. 1991: 187-197.
14. Halaban R. Culture of melanocytes from normal, benign and malignant lesions. In: Pfragner R, Freshney RI, eds. Culture of Human Tumor Cells. Hoboken, New Jersey: Wiley and Sons. 2004: 289-318.
15. Twentyman PR. Lung Cancer. In: Masters JRW, ed. Human Cancer in Primary Culture, A Handbook. Dodrecht: Kluwer Academic Publishers. 1991: 199-229.
16. Wu Reen. Growth of human lung tumor cells in culture. In: Pfragner R, Freshney RI, eds. Culture of Human Tumor Cells. Hoboken, New Jersey: Wiley and Sons. 2004: 1-21.
17. Darling JL. In vitro culture of malignant brain tumors. In: Pfragner R, Freshney RI, eds. Culture of Human Tumor Cells. Hoboken, New Jersey: Wiley and Sons. 2004: 349-372.
18. Whelan RDH, Hosking LK, Shellard SA, Hill BT. Ovarian tu-mours. In: Masters JRW, ed. Human Cancer in Primary Culture, A Handbook. Dodrecht: Kluwer Academic Publishers. 1991: 253-260.
19. Wilson AP. The development of human ovarian epithelial tu-mor cell lines from solid tumors and ascites. In: Pfragner R, Freshney RI, eds. Culture of Human Tumor Cells. Hoboken, New Jersey: Wiley and Sons. 2004: 145-178.
20. Harper ME. Prostate. In: Masters JRW, ed. Human Cancer in Primary Culture, A Handbook. Dodrecht: Kluwer Academic Publishers. 1991: 261-269.
21. Bright KR, Lewis JD. Long-term culture of normal and malig-nant human prostate epithelial cells. In: Pfragner R, Freshney RI, eds. Culture of Human Tumor Cells. Hoboken, New Jersey: Wiley and Sons. 2004: 125-144.
22. O'Hare MJ. Breast cancer. In: Masters JRW, ed. Human Cancer in Primary Culture, A Handbook. Dodrecht: Kluwer Academic Publishers. 1991: 271-286.
23. Speirs V. Primary culture of human mammary tumor cells. In: Pfragner R, Freshney RI, eds. Culture of Human Tumor Cells. Hoboken, New Jersey: Wiley and Sons. 2004: 205-219.
24. Stern P, West C, Burt D. Culture of cervical carcinoma tumor cell lines. In: Pfragner R, Freshney RI, eds. Culture of Human Tumor Cells. Hoboken, New Jersey: Wiley and Sons. 2004: 179-204.
25. Fu VX, Schwarze SR, Reznikoff CA, Jarrad DF. The establish-ment and characterization of bladder cancer cultures in vitro. In: Pfragner R, Freshney RI, eds. Culture of Human Tumor Cells. Hoboken, New Jersey: Wiley and Sons. 2004: 97-123.
26. Edington KG, Berry IJ, O'Prey M, Burns JE, Clark LJ, Mitchell R, Robertson G, Soutar D, Coggins LW, Parkinson EK. Multistage head and neck squamous cell carcinoma. In: Pfragner R, Freshney RI, eds. Culture of Human Tumor Cells. Hoboken, New Jersey: Wiley and Sons. 2004: 261-288.
27. Jguchi H, Mizumoto K, Shono M, Kono A, Takiguchi S. Pank-reatic cancer-derived cultured cells: genetic alterations and ap-plication to an experimental model of pancreatic cancer metas-tasis. In: Pfragner R, Freshney RI, eds. Culture of Human Tu-mor Cells. Hoboken, New Jersey: Wiley and Sons.2004: 81-96.
28. Volm M, Kaufmann K, Hinderer H, Goerttler Kl: Schnellme-thode zur Sensibilitätstestung maligner Tumoren gegenüber Cytostatica. Klin Wschr. 1970; 48: 374-376.
29. Reinhold U, Tilgen W. Chemosensitivity Testing in Oncology. Berlin: Springer; 2003.
30. Blumenthal RD. Chemosensitivity Vol 1, In Vitro Assays. To-towa, New Jersey: Humana Press; 2005.
31. Kern DH, Weisenthal LM: Highly specific prediction of antineoplastic drug resistance with an in vitro assay using su-prapharmacologic drug exposures. J Natl Cancer Inst. 1990; 82: 582-588.
32. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleibermann I, Caruso PA, Ricks SH, Untch M, Satori C, Bruckner HW: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate lumines-cence assay: clinical correlation for cisplatine resistance of ovarian carcinoma. Cancer Res. 1995; 55: 5276-5282.
33. Selby P, Buick RN, Tannock I: A critical appraisal of the human tumor stem-cell assay. New Engl J Med. 1983; 308: 129-134.
34. Weisenthal LM: Fresh-tumor, cell-culture assays for breast cancer. In: Dickson RB, Lippman ME, eds. Drug and Hormonal Resistance in Breast Cancer. New York: Ellis Horwood, 1995: 323-349.
35. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Sommerfield M: American Society of Clinical Oncology Tech-nology Assessment: Chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004; 22: 3631-3638.
36. Fruehauf JP, Alberts DS: In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol. 2005; 23: 3641-3643.
37. Mattern J, Volm M: Clinical relevance of predictive tests for cancer chemotherapy. Cancer Treatment Reviews. 1982; 9: 267-298.
38. Weisenthal LM. Predictive assays for drug and radiation re-sistance. In: Masters JRW, ed. Human Cancer in Primary Cul-ture. Dodrecht: Kluwer Academic Publishers. 1991: 103-147.
39. Cree IA: Chemosensitivity and chemoresistance testing in ovarian cancer. Curr Opin Obstet Gynecol. 2009; 21: 39-43.
40. Havrilesky LJ, Krivac TC, Mucenski JW et al. Impact of chemoresponse assay on treatment costs for recurrent ovarian cancer. Am J Obstet Gynecol. 2010; 203: 1-7.
41. [Internet] NCCN. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology; Ovarian Cancer. http://www.NCCN.org
42. Kubota T, Weisenthal L: Chemotherapy sensitivity and re-sistance testing: to be "standard" or to be individualized, that is the question. Gastric Cancer 2006; 9: 82-87.
43. Bosanquet AG: Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. Lancet. 1991; 337: 711-714.
44. Bosanquet AG, Richards SM, Wade R, Else M, Matutes E, Dyer MJ, Rassam SM, Durant J, Scadding SM, Raper SL, Dearden CE, Catovsky D: Drug cross-resistance and therapy-induced re-sistance in chronic lymphocytic leukaemia by an enhanced method of indivi-dualised tumour response testing. Br J Hae-matol. 2009; 146: 384-395.
45. Galderisi F, Stork L, Li J, Mori M, Mongoue-Tchokote S, Huang J: Flow cytometric chemosensitivity assay as a predictive clini-cal response in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009; 53: 543-550.
46. Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK: Tumor markers, Physiology, Pathobiology, Technology, and Clinical Applications. Washington DC: AACC Press; 2002.
47. [Internet] National Cancer Institute, Division of Cancer Pre-vention. Early Detection Research Network Progress Reports; Initial Report, October 2000. http://www.edrn.nci.nih.gov/docs.
48. [Internet] National Cancer Institute, Division of Cancer Pre-vention. Early Detection Research Network Progress Reports; Fourth Report, January, 2008. http://www.edrn.nci.nih.gov/docs.
49. Nass SJ, Moses HL. Cancer Biomarkers, The Promises and Challenges of Improving Detection and Treatment. Washington DC: The National Academies Press; 2007.
50. Kurzrock R, Markman M: Targeted Cancer Therapy. Totowa, New Jersey: Humana Press; 2008.
51. Chang DZ, Kumar V, Ma Y, Li K, Kopetz S: Individualized therapies in colorectal cancers: KRAS as a marker for response to EGFR-targeted therapy. J Hematol Oncol. 2009; 2: 18.
52. Volm M, Rittgen W: Cellular predictive factors for the drug rersponse of lung cancer. Anticancer Research 2000; 20: 3449-3458.
53. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K: Micro RNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008; 68: 10307-14.
54. Seve P, Reiman T,.Dumontet C: The role of beta III tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer. 2010; 67: 136-143.
55. Hodgkinson VC, Eagle GL, Drew PJ, Lind MY, Cawkwell L: Biomarkers of chemotherapy resistance in breast cancer identi-fied by proteomics: Current status. Cancer Letters. 2010; 294: 13-24.
56. Dupuy A, Simon RM: Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst. 2007; 99: 147-157.
57. Kawasaki ES: The end of the microarray Tower of Babel: will universal standards lead the way? J Biomol Tech. 2006; 17: 200-206.
58. Larson SM, Schwartz LH:18F-FDG PET as a candidate for "qualified biomarker": Functional assessment of treat-ment response in oncology. J Nucl Med. 2006; 47: 901-903.
59. Weber W. Assessing tumor response to therapy. J Nucl Med. 2009; 50: 1S-10S.
60. Hutchings M, Barrington SF: PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009; 50: 21S-30S.
61. Hicks RJ: Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med. 2009; 50: 31S-42S.
62. de Geus-Oei LF, Vriens D, van Laarhoven HWM, van der Graaf WTA, Oyen WJG: Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic re-view. J Nucl Med. 2009; 50: 43S-54S.
63. Avril N, Sassen S, Roylance R: Response to therapy in breast cancer. J Nucl Med. 2009; 50: 55S-63S.
64. Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D: The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med. 2009; 50: 64S-73S.
65. Schöder H, Fury M, Lee N, Kraus D: PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med. 2009; 50: 74S-88S.
66. Krause BJ, Herrmann K, Wieder H, zum Büschenfelde CM: 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer. J Nucl Med. 2009; 50: 89S-96S.
67. Boellaard R: Standards of PET image acquisition and quantita-tive data analysis. J Nucl Med. 2009; 50: 11S-20S.
68. Contractor KB, Aboagye EO: Monitoring predominantly cyto-static treatment response with 18F-FDG PET. J Nucl Med. 2009; 50: 97S-105S.
69. Mankoff DA, Krohn KA. PET imaging of response and re-sistance to cancer therapy. In: Teicher BA, ed. Cancer Drug Re-sistance. Totowa, New Jersey: Humana Press; 2006: 105-122.
70. Dunphy MPS, Lewis JS: Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med. 2009; 50: 106S-121S.
71. Institute of Medicine. Improving the quality of cancer clinical trials: Workshop summary. Washington DC: The National Academies Press; 2008.
72. Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S et al. Cancer cell adaption to chemotherapy. BMC Cancer. 2005; 5: 78.
73. Wahl RL, Jacene H, Kasamon Y, Lodge MA: From RESIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50: 122S-150S.
74. Bosanquet N, Sikora K: The Economics of Cancer Care. Cam-bridge: Cambridge University Press; 2006.